| Document |
Document Title |
|
WO/1994/004555A1 |
New steroids with an annulated five-membered ring have general formula (I), in which Y stands for an oxygene or sulphur atom or for a sulfonyl group or for the groups (a) or (b), in which X stands for a hydrogen atom, a saturated, straig...
|
|
WO/1994/001450A1 |
The invention concerns a method of preparing 14,17alpha-etheno- and 14,17alpha-ethano-16alpha,17beta-steroiddiols and derivatives thereof, in particular 14,17alphaetheno- and 14,17alpha-ethano-3,16alpha,17beta-estriols and their esters, ...
|
|
WO/1994/001118A1 |
Methods for enhancing the transport of pharmacologically active substances across mucous membranes of an animal by administration of pharmaceutical compositions comprising modified saponins or fractions thereof obtainable by modification...
|
|
WO/1993/025568A2 |
Novel antihypercholesterolemic agents are provided. An exemplary group of compounds has structural formula (I), wherein R is a C-17 side chain, R?1¿ is -OH, =O, or the like, R?8¿ and R?9¿ are independently hydrogen or lower alkyl, and...
|
|
WO/1993/023020A1 |
Competitive progesterone antagonists, including two novel steroids, viz., 11$g(b),19-[4-(cyanophenyl)-o-phenylene]-17$g(b)-hydroxy-17$
g(a)-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11$g(b),19-[4-(3-pyridinyl)-o-phenylene]-17$g(b)-...
|
|
WO/1993/010741A2 |
Inhibitors of sex steroid activity, for example those having general structure (A) may be used as part of a pharmaceutical composition to provide antiestrogenic effects and/or to suppress estrogen synthesis. Such pharmaceutical compositi...
|
|
WO/1993/006124A1 |
11$g(b)-substituted 14,17-ethanoestratrienes have general formula (I), in which R?1¿ stands for a hydrogen atom, a C¿1?-C¿12?-alkanoyl group, a straight- or branched-chain C¿1?-C¿12?-alkyle, a C¿3?-C¿7?-cycloalkyle or a C¿4?-C¿8...
|
|
WO/1993/005063A1 |
Novel steroid sulphatase inhibitors are disclosed as well as pharmaceutical compositions containing them for use in the treatment of oestrone dependent tumours, especially breast cancer. The novel steroid sulphatase inhibitors are sulpho...
|
|
WO/1992/019641A1 |
The description relates to the novel 14$g(a),16$g(a)-ethano and 14$g(a),16$g(a)-etheno estratienes of the general formula (I) in which: A-B is a C-C single or C-C double bond, R�1? is a hydrog en atom, a methyl or acyl group with 1-12 ...
|
|
WO/1992/019642A1 |
14$g(a),17$g(a)-(propano and 17?2�-propeno) estratrienes of the general formula (I), in which R?1� is a hydrogen atom, a methyl or acyl group with 1-12 carbon atoms, R?2� is a hydrogen atom or an acyl group with 1-12 carbon atoms a...
|
|
WO/1992/012990A1 |
Described are 14,16$g(b)-ethano-15$g(b)-16?1� -cyclo-14$g(b)-estra-1,3,5(10)-trienes of the general formula (I), in which R?1� is a hydrogen atom, a C�1?-C�9? alkyl residue or a C�1?-C�9? acyl residue; R?2� is a hydrogen at...
|
|
WO/1992/009618A1 |
Described are 8-ene-19, 11$g(b)-bridged steroids of general formula (I) which have a new structural feature in the form of a double bond between the 8 position and the 9 position. Also described is a method of preparing them. The substit...
|
|
WO/1991/008219A1 |
The description relates to novel 14-$g(a),17-$g(a)-bridged estratrienes of general formula (I) in which: if OR?3¿ is alpha-permanent; R?1¿, R?2¿ and R?3¿ are independently a hydrogen atom, an acyl group (a) in which R?4¿ is an organ...
|
|
WO/1991/001994A1 |
The invention relates to 11$g(b)-substituted 16$g(a),17$g(a)-methylene-estra-4,9-diene-3-ones of general formula (I), where R?1� is a methyl or ethyl group, R?2� is a hydrogen atom, an alkyl, alkoxymethyl, alkanol or alkoxycarbonyl g...
|
|
WO/1991/001993A1 |
The invention relates to new 11$g(b)-aryl-16$g(a),17$g(a)-cyclohexano-estra-4,9-dienes of general formula (I), where R?1� is a hydrogen atom or a methyl group, R?2� is OCH�3?, SCH�3?, N(CH�3?)�2?, NHCH�3?, CN, CHO, COCH�3...
|
|
WO/1990/014354A1 |
Steroids with a 9$g(a)-hydroxy-19,11$g(b) bridge, of general formula (I), in which A, B, R?1¿, R?2¿, G, Z, R?4¿-Y- and R?4'¿-Y'- have the meanings given in the description. The steroids of general formula (I) have an antigestagenic a...
|
|
WO/1990/005139A1 |
New 14alpha,17alpha-ethano-estratrienes of general formula (I) wherein R1 is a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms, R2 is a hydrogen atom or a methyl group, R3 is a hydrogen atom or an acyl group with 1 to 12 ...
|
|
WO/1990/003385A1 |
New 11beta-phenyl-14betaH-steroids of general formula (I), where Z is an oxygen atom or the hydroxyimino-grouping N ~ OH, and M and N are either jointly a second compound or L is a hydrogen atom and M is an alpha-permanent hydroxy group ...
|
|
WO/1990/000560A1 |
Steroid compounds represented by general formulae (I), (II) or (III), wherein R1 and R2 each represents a hydrogen atom or a hydroxyprotecting group, R represents -CH2-X, a carboxyl group or a protected carboxyl group, X represents a sub...
|
|
WO/1989/012448A1 |
An 11beta-aryl-19-norprogesterone steroid of formula (I): wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, ...
|
|
WO/1988/007051A1 |
New 19, 11beta-bridged steroids having the general formula (I), in which R' signifies a methyl or ethyl residue; R2 signifies a hydrogen or chlorine atom or a C1-C4 alkyl residue; B and G, which are identical or different, signify respec...
|
|
WO/1988/001275A1 |
Agents having an oestrogenic activity, containing a compound of general formula (I), where R<1> represents a hydrogen atom, a methyl group or an acyl group with 1 to 12 carbon atoms, R<2> represents a hydrogen atom or an acyl group with ...
|
|
WO/1987/006937A1 |
2,2;6,6-diethylene-3-oxo-17alpha-pregn-4-en-21,17-carbolacto
nes of general formula (I), wherein R1 is a hydrogen atom or a methyl group, R2 is a methyl or ethyl group and (II), (III) or (IV), as well as process for their production, and...
|
|
WO/1987/006237A1 |
A process is used for producing 7alpha-propylsteroids having general formula (I), wherein R1 is a beta-hydroxy group and R2 is hydrogen or a alpha linked -CH2-CH2COOR5 residue, R1 and R2 form together the residue (A), R3 and R4 are hydro...
|
|
WO/1987/003599A1 |
A process for producing 7alpha-acetylsteroids having the formula (I), in which R1, R2, R3 and R4 are hydrogen or (a) is the group (b) and (c) is the group (d). The process is characterized by the fact that a 3-oxo-17alpha-pregna-4,6-dien...
|
|
WO/1986/004900A1 |
New 1alpha.7alpha-dithio substituted spirolactones having the general formula (I) wherein R1 is C1-3-alkyl and C1-3-acyl and R2 is hydrogen, C1-3-alkyl and C1-3-acyl, preparation thereof and utilization thereof as drug. The compounds hav...
|
|
WO/1986/000312A1 |
Cycloartenyl ferulate-cyclodextrin complex can be prepared by including cycloartenyl ferulate, a difficultly water-soluble component of gamma-oryzanol, with cyclodextrin. The complex has an increased water solubility and an improved abso...
|
|
WO/1985/005622A1 |
New derivatives of vitamin D3 and specifically (22E,24R)-1,24-dihydroxy-DELTA22-vitamin D3 and (22E,24S)-1,24-dihydroxy-DELTA22-vitamin D3. The compounds exhibit vitamin D-like activity in their ability to stimulate intestinal calcium tr...
|
|
WO/1985/005623A1 |
An agent for treating arteriosclerosis, which contains as effective ingredient cycloartenol ferulate, a component of gamma-oryzanol. This agent shows excellent effects of lowering a total cholesterol level, a free cholesterol level, a ne...
|
|
WO/1985/000818A1 |
New derivative of vitamin D, 23,23-difluoro-25-hydroxycholecalciferol, a method for preparing said compound and various new intermediates utilized in such process. The compound is characterized by vitamin D-like activity as evidenced by ...
|
|
WO/1985/000819A1 |
New derivative of vitamin D, 23,23-difluoro-1,25-dihydroxycholecalciferol. The compound is characterized by vitamin D-like activityas evidenced by its ability to increase intestinal calcium transport. It is further characterized by its r...
|
|
WO/1984/001155A1 |
Hydroxylated derivatives of vitamin D2., processes for preparing such compounds, intermediates utilized in such processes and certain isotopically labelled vitamin D2 compounds. The vitamin D2 derivatives would find application in the tr...
|
|
WO/1983/003099A1 |
The invention relates to products having the general formula I, wherein R1 is thienyl or phenyl optionally substituted, furyl, cycloalkyl, naphtyl, phenyl-phenyl, alkyl or alkenyl; R2 is methyl or ethyl; R3 is H, OH, alkyl, alkenyl, opti...
|
|
WO/1982/000294A1 |
5(Beta)-hydroxy-(Alpha)6-steroid derivatives having the general formula (FORMULA) wherein R1 represents a hydrogen atom, an acyl, lower alkyl or tetrahydropyranyl residue and R2, R3 each a hydrogen atom or in common a methylene residue a...
|
|
WO/1980/002562A1 |
Isotopically labeled vitamin D compounds, including radiolabeled vitamin D compounds of high specific activity, methods for their preparation, and novel intermediates in their synthesis. The radiolabeled vitamin D compounds are character...
|
|
JP2024045458A |
The present invention provides steroidal derivative modulators, methods of making and using the same. The present invention relates to steroidal derivative modulators, their production methods and applications. In particular, the present...
|
|
JP7438956B2 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
JP2023550653A |
Provided herein are compounds of formula (I) or a pharmaceutically acceptable salt thereof, where Ring D and substituents are as defined herein. Also provided are pharmaceutical compositions comprising a compound of formula (I) or a phar...
|
|
JP2022543576A |
The present invention provides steroid derivative modulators, in particular formula (I) , salts and crystalline forms thereof, processes for their preparation, pharmaceutical compositions containing therapeutically effective amounts of t...
|
|
JP2022536698A |
Kind Code: A1 The present invention provides naturally occurring compounds, specifically guaurine A, B, C and D for use in medicine, which are non-cytotoxic and non-genotoxic to healthy lymphocytic cells. Kind Code: A1 Argentatin A and C...
|
|
JP7093595B2 |
The present invention provides a method for preparing oryzanol from oryzanol-containing soapstock serving as a raw material, comprising the following steps: 1) alkali-alcohol thermal dissolution; 2) heat-preserved fine filtration; 3) hea...
|
|
JP2021512909A |
The present invention relates to a steroidal derivative modulator, a method for producing the same, and an application thereof. The present invention particularly relates to a compound represented by the general formula (I), a method for...
|
|
JPWO2019188490A1 |
An object of the present invention is to provide a composition for improving ultraviolet resistance. A means for solving this problem is to use one or more compounds selected from the group consisting of a lophenol compound and a cyclola...
|
|
JP6776326B2 |
Method for the separation of at least one isoprenic constituent from the resin of a plant of guayule and/or of the guayule type comprising the steps of: a) providing a defatted resin of guayule and/or of the guayule type; b) subjecting t...
|
|
JP2018505216A |
The present invention relates to C-3 novel triterpenones and C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases, especially HIV-mediated diseases.
|
|
JP5916279B2 |
|
|
JP5898731B2 |
The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)-17β-hydroxysteroids of the formula I starting from 17-ketosteroids of the formula III via the intermediates of the formula V wherein the radicals R...
|
|
JP2016041770A |
To provide methods and compositions for increasing telomerase activity in cells.Such compositions include pharmaceuticals, including topical and nutraceutical formulations. The methods and compositions are useful for treating diseases re...
|
|
JP5872074B2 |
The present invention relates to a lupane triterpenoid derivatives and pharmaceutical use thereof, specifically relates to a lupane triterpenoid derivatives of formula (I)˜(III), a pharmaceutical composition and a combination preparatio...
|
|
JP5830013B2 |
The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatm...
|
